Company Filing History:
Years Active: 2006
Title: Jesper Hanning: Innovator in Therapeutic Vaccination
Introduction
Jesper Hanning is an accomplished inventor based in Birkerød, Denmark, known for his groundbreaking work in the field of therapeutic vaccination. With a strong dedication to advancing medical science, he has developed innovative methods that aim to enhance cell-mediated immunity against cellular antigens.
Latest Patents
Hanning holds a patent that details a novel method for inducing cytotoxic T-lymphocyte immunity against weak antigens, especially self-proteins. The invention focuses on a technique where antigen-presenting cells present at least one cytotoxic T-lymphocyte (CTL) epitope of a weak antigen while simultaneously presenting a foreign T-helper lymphocyte epitope. This approach is particularly significant in the context of cancer-specific antigens, such as PSM, Her2, or FGF8b. The method can be implemented through traditional polypeptide vaccination, as well as live attenuated vaccines or nucleic acid vaccinations. Additionally, the patent includes immunogenic analogues of the mentioned antigens, nucleic acid molecules encoding these analogues, and the vectors and transformed cells used in the process. It also proposes a method for identifying immunogenic analogues of weak or non-immunogenic antigens.
Career Highlights
Jesper Hanning has made a significant impact in the field of immunology through his work at Pharmexa A/S, where he has focused on developing therapeutic strategies to combat cancer. His innovative approach to vaccination has potentially transformative implications for the treatment of various cancer types and enhancing the body’s immune response.
Collaborations
Throughout his career, Hanning has collaborated with esteemed professionals, including Lucilla Steinaa and Søren Mouritsen. These partnerships have enabled him to leverage diverse expertise and drive the development of cutting-edge immunological treatments.
Conclusion
In conclusion, Jesper Hanning stands out as a valuable inventor in the realm of therapeutic vaccination. His patent contributions and collaborative endeavors at Pharmexa A/S reflect his commitment to advancing cancer immunotherapy and improving patient outcomes. With continued research and innovation, Hanning’s work holds promise for significant advancements in medical science.